Work

A phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) endometrial cancer (EC).

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.15_suppl.tps5611

Authors: Rebecca L. Porter, Jennifer Taylor Veneris, Nabihah Tayob, Gabriela West, Madeline Polak, Jeanette Gardner, Susana M. Campos, Carolyn N. Krasner, Elizabeth Katherine Lee, Joyce F. Liu, Elizabeth Stover, Alexi A. Wright, Ursula A. Matulonis, Panagiotis A. Konstantinopoulos

Institution: Dana-Farber Cancer Institute

Language: English

Topic: Endometrial and Cervical Cancer Treatments

Subfield: Obstetrics and Gynecology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3168662852

Cites:

Cited by: 3

Related to: 10